Trials / NCT05183802
An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)
Approved for marketing N/A Drug / neuroprotection
- Sponsor
- Rhythm Pharmaceuticals, Inc.
- Treatment
- Setmelanotide, administered subcutaneously [SC], once daily.
- Gene
- Not stated
- Conditions
- Bardet-Biedl Syndrome (BBS), Obesity
- Ages
- 6 Years to no upper limit
- Enrollment
- Not stated participants
- Started
- Not stated
- Main results expected
- Not stated
- Results posted
- Not yet
- Record last updated
- 2022-08-10
What the study is testing
An open-label, single-arm, multicenter, Expanded Access Protocol [EAP] designed to provide treatment access to setmelanotide (3 mg, administered subcutaneously [SC], once daily) for eligible patients with BBS who have no alternative treatment options. All patients will continue to receive setmelanotide at the discretion of the Treating Physician and while they are deriving clinical benefit.
Where it runs
No sites listed yet.